Adult Immunization

New data show the LP.8.1-adapted COVID-19 vaccine generates ≥4-fold antibody increases in older and high-risk adults, with no new safety concerns.

A secondary analysis of the DANFLU-2 trial found adults ≥65 receiving a high-dose flu vaccine had a 46% lower risk of myocarditis or pericarditis compared with standard-dose vaccination.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

More than 90% of adults making nonurgent ED visits had missed at least 1 CDC-recommended vaccine but many were willing to catch up on all of them while there.

Z-1018, which combines a glycoprotein E (gE) antigen and proprietary adjuvant, was evaluated in adults aged 50 to 69 and the 100 µg dose will advance to part 2 of the trial.

New data show more than one-third of US adults are unaware of HPV or the HPV vaccine, with gaps greatest in the Midwest and South, where HPV-related cancers are most common.

Infectious disease expert Amesh Adalja, MD, discusses new vaccine policies, misinformation, and how PCPs can build confidence during National Immunization Awareness Month.

A recent poll reveals most US adults are hesitant about fall COVID-19 vaccinations, highlighting confusion over federal policies and declining trust in health agencies.